India, Feb. 11 -- Drug major Pfizer Inc. (PFE) and Japan's Astellas Pharma Inc. announced late Monday additional follow-up results from the Phase 3 EV-302 clinical trial, also known as KEYNOTE-A39, evaluating the efficacy and safety of PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial cancer or la/mUC.
The trial results showed a sustained overall survival or OS and progression-free survival or PFS benefit, which was consistent with the findings of the primary analysis after an additional 12 months of follow-up (median follow-up of 29.1 months).
Seagen's and Astellas' PADCEV is a Nectin-4 directed antibody-drug conjugate, while Merck's KEYTRUDA is ...